Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Imunon, Inc. before investing.

In this article, we go over a few key elements for understanding Imunon, Inc.’s stock price such as:

• Imunon, Inc.’s current stock price and volume
• Why Imunon, Inc.’s stock price changed recently
• Upgrades and downgrades for IMNN from analysts
• IMNN’s stock price momentum as measured by its relative strength

About Imunon, Inc. (IMNN)

Before we jump into Imunon, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Want to learn more about Imunon, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Imunon, Inc..

Imunon, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 1:01 PM, CST, Imunon, Inc.’s stock price was $1.635.

Imunon, Inc. is up 0.92% from its previous closing price of $1.620.

During the last market session, Imunon, Inc.’s stock traded between $1.560 and $1.720. Currently, there are approximately 14.56 million shares outstanding for Imunon, Inc..

Imunon, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Imunon, Inc. Stock Price History

Imunon, Inc.’s (IMNN) price is currently down 34.34% so far this month.

During the month of June, Imunon, Inc.’s stock price has reached a high of $3.160 and a low of $1.270.

Over the last year, Imunon, Inc. has hit prices as high as $3.650 and as low as $0.370. Year to date, Imunon, Inc.’s stock is up 72.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Imunon, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there was 1 analyst who downgraded Imunon, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Imunon, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Imunon, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Imunon, Inc. (IMNN) by visiting AAII Stock Evaluator.

Relative Price Strength of Imunon, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Imunon, Inc. has a weighted four-quarter relative price strength of 21.42%, which translates to a Momentum Score of 93 and is considered to be Very Strong.

Want to learn more about how Imunon, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Imunon, Inc. Stock Price: Bottom Line

As of June 11, 2025, Imunon, Inc.’s stock price is $1.635, which is up 0.92% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Imunon, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.